Kim-Hien Dao is a Hematology physician. OpenAlex indexes 35 publications with 3,051 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
875 Oak St SE Ste 4030
Salem, OR 973013984
Telephone
503-561-6444Provider last certified this registry record 21 Jan 2021.
Clinical trials
1 registered study on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20241 payment
- Acrotech Biopharma Inc.Program year20241 payment
- E.R. Squibb & Sons, L.L.C.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
3 NIH research awards on record, funded 2012–2019 per NIH RePORTER. The latest:
- Immune checkpoint abnormalities in human subjects with clonal hematopoiesis
Oregon Health & Science University
FY2019$77,000R03HL144898 - Defining monocyte abnormalities caused by age-associated mutations in epigenetic regulatory genes
Oregon Health & Science University
FY2018$231,000R21AG055695 - Immune checkpoint abnormalities in human subjects with clonal hematopoiesis
Oregon Health & Science University
FY2018$77,000R03HL144898
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
Journal of Clinical Oncology
2019 - Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years
Hematology/Oncology and Stem Cell Therapy
2019
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Joseph Antin, MD
Harvard University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”